Additionally, Di Mauro P et al. reported that the overexpression of LOX (but not LOXL2) in triple-negative breast cancer cells leads to a significant increase in the production of IL-6, a pro-osteoclastic cytokine; they proposed a model suggesting that the combined action of LOX and IL-6, which are secreted by tumour cells, synergistically enhances osteoclast-mediated bone resorption, ultimately promoting the destruction of metastatic bone in vivo46. Here, LOX is linked to neoplasm.